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The clinical potential of cell-based therapies is 
limited by poor targeting of systemically infused cells 
to diseased tissues [1]. In our recent study, we have 
developed a multi-step screening platform to identify 
small molecules that boost the homing properties of 
mesenchymal stem cells (MSCs) to sites of inflammation 
[2]. First, a medium-throughput screen was designed 
to identify small molecules that upregulate surface 
expression of the homing integrin, cd11a (integrin αL). 
Ro-31-8425, a kinase inhibitor, was identified as the 
most potent inducer of cd11a surface expression, and was 
also shown to significantly increase MSC firm adhesion 
to the endothelial ligand of cd11a, ICAM-1, using a 
microfluidics-based firm adhesion assay [3]. Finally, 
systemically infused Ro-31-8425-pretreated MSCs 
displayed improved homing to sites of inflammation 
and a superior anti-inflammatory impact in a murine ear 
inflammation model. 
Using small molecule pretreatment to control cell 
behavior post-infusion possesses multiple advantages 
over other bioengineering approaches, such as chemical 
surface modification or DNA engineering. Small 
molecule-induced transient modification of signaling 
pathways offers a potentially safe, simple, cost-effective 
and highly scalable approach. Moreover, the described 
versatile multi-step screening platform can be readily 
tweaked to potentially target virtually any cell type to 
multiple sites in the body. This platform consists of four 
essential steps: i) Screening small molecule libraries to 
identify compounds that induce expression of molecules 
of interest; ii) Functional validation of hits from the first 
step to assess the corresponding functional properties 
of pretreated cells; iii) In-vivo functional validation 
step to evaluate the function of pretreated cells in the 
suitable disease model; iv) Assessing therapeutic efficacy 
following infusion of pretreated cells. This platform can 
be customized by modifying the first screening step to 
identify small molecule inducers of other disease-specific 
homing ligands/chemokine receptors and by altering 
the in-vitro functional step to assess homing properties 
corresponding to a key step in the cell homing cascade 
(i.e., rolling, chemokine-directed migration and firm 
adhesion) [4]. Secretion of chemokines and expression of 
homing receptors on the endothelium of multiple tissues 
during disease onset can both be used for targeting [4]. 
For instance, inducing expression of CXCR1, Mac-1 and 
CXCR4 may target infused cells specifically to sites of 
myocardial infarction, expression of CXCR3 and LFA-1 
may shuttle cells to the diseased brain in multiple sclerosis 
patients and expression of CCR9 and α4β7 may direct 
cells to the inflamed intestine characteristic of Crohn’s 
disease [4]. Tailoring the steps of this platform to target 
disease-specific endothelial cell phenotypes, may help 
identify small molecules for preconditioning to promote 
precise targeting of infused cells to potentially any 
clinically relevant site.
The use of multi-molecule cocktails to 
simultaneously control multiple cell properties is another 
advantage of using small molecule preconditioning. 
Such cocktails may be used to up-regulate multiple 
homing receptors corresponding to different steps of the 
homing cascade to maximize the cell homing response. 
Furthermore, this approach may be used to concurrently 
control cell homing as well as engineer cellular therapeutic 
cargo, creating a cell-based targeted delivery platform. For 
instance, the MSC secretome is considered the primary 
mechanism mediating its therapeutic impact [5]. Upon 
infusion the MSC secretome is unpredictable due to 
exposure to the highly variable host microenvironments, 
and improved control over its composition and release 
kinetics via small molecule preconditioning may 
significantly boost the clinical impact of infused cells. 
In this case, the first screening step could be replaced 
with a secretion assay. For instance, boosting secretion 
of angiogenic factors such as VEGF may be beneficial 
for cell-based treatment of cardiovascular diseases, cells 
secreting neurotrophic factors such as BDNF would 
be useful for potentially treating multiple sclerosis and 
interleukin-10 secretion may be beneficial in suppressing 
the inflammatory response in Crohn’s disease. Overall, 
using a small molecule combination to promote efficient 
targeting of infused cells to sites of disease, where cells 
will secrete high doses of disease-specific therapeutic 
cytokines, presents a promising strategy to potentially 
create highly potent, disease-targeted cell therapies.
Finally, small molecules may also be used to 
control cell fate from the inside out. This can be achieved 
via encapsulation of small molecules in polymeric 
microparticles, which are then loaded into the cells. For 
instance, we have recently shown that loading cells with 
the glucocorticoid drug, budesonide, augments MSC 
immunosuppressive properties via IDO upregulation 
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[6]. We have also reported that dexamethasone-doped 
microparticles loaded into MSCs facilitated controlled 
release of dexamethasone intra- and extra-cellularly to 
promote osteogenic differentiation of both drug-loaded 
cells and surrounding and distant cells [7]. Administration 
of cells loaded with small molecule-doped microparticles 
can thus be used not only to improve control over the 
phenotype of infused cells, but also as a cellular delivery 
platform of therapeutic agents. Overall, the development 
of modular screening platforms to identify potent small 
molecules that can be used to control cell fate via 
“traditional” preconditioning or through next-generation 
biomaterial-based platforms presents a powerful and 
versatile strategy for rapidly advancing the clinical 
translation of cell-based therapies.
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